组织芯片检测乳腺癌相关癌基因产物表达

Evaluate the expression of associated genes production in breast carcinoma by the application of tissue microarray

目的 检测乳腺癌相关癌基因产物的表达情况 ,为临床制定治疗方案和判断预后提供依据。方法 运用组织芯片技术、免疫组化S P法检测 48例乳腺癌ER、PR、p5 3、c erbB 2、Ki 6 7、TopoⅡ和E cadherin(E cad)的表达情况 ,并与常规病理学方法进行比较。结果 48例乳腺癌中ER阳性 32例、PR阳性 36例、p5 3阳性 42例、c erbB 2阳性 31例、Ki 6 7阳性 45例、TopoⅡ阳性 41例 ;44例浸润性导管癌中 ,E cad阳性 37例 ;而 4例浸润性小叶癌E cad均阴性。对照组的 13例乳腺组织均E cad呈阳性表达。随访 :44例浸润性导管癌中 3例死亡 (6 8%) ;4例浸润性小叶癌中 2例死亡 (5 0 0 %)。结论 组织芯片技术具有高信息量、简捷、快速、高效、成本低、重复性好等优点 ,在病理学领域中具有重要的实际意义和广阔的应用前景。

Purpose To evaluate the expression of associated genes production of breast carcinoma, to give evidences for clinical therapy programs and judgment of prognosis. Methods Tissue microarray technology and immunohistochemistry were used to detect the expression of ER, PR, p53, c-erbB-2, Ki-67, TopoⅡand E-cad in 48 cases of breast carcinoma. Compared the result with the traditional pathological investigation. Results In 48 cases of breast carcinoma, there were 32 cases of ER positive, 36 cases of PR positive, 42 cases of p53 positive, 31 cases of c-erbB-2 positive, 45 cases of Ki-67 positive and 41 cases of TopoⅡ positive. In 44 cases of invasive ductal carcinoma, 37 cases were E-cad positive, while 4 cases of invasive lobular carcinoma were E-cad negative. 13 cases of benign lesion were E-cad positive. Follow up: 3(6.8%) of 44 cases of invasive ductal carcinoma died; 2 (50.0%) of 4 cases of invasive lobular carcinoma died. Conclusions Tissue microarray technology has the advantages of high-throughput, conciseness, rapidity, high efficiency, low cost, nice reproducibility, etc. It has important practical significance and broad application prospect in pathology.